TNFRSF10B and neoplasm: Both DR4 (CD261) and DR5 (CD262) possess four to five potential O-glycosylation sites, and mutations in the DR5 were previously reported to inhibit the TRAIL-mediated apoptosis, suggesting that O-glycosylation of the TRAIL/DR5 complex controls the sensitivity of tumor cells to the preapoptotic TRAIL ligand [18].